Hsieh C.-Y.TSEN-FANG TSAI2021-10-282021-10-2820212193-8210https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104375038&doi=10.1007%2fs13555-021-00524-w&partnerID=40&md5=3f4c614a68ba13f8c007e6a6abd6ac71https://scholars.lib.ntu.edu.tw/handle/123456789/585976H-1 antihistamines are commonly used in dermatological practice for itch and urticaria control. The widespread expression of H-1 receptor on different cells in the skin and various biologic functions of H-1 antihistamines indicate the possible treatment potentials of H-1 antihistamines in dermatology. A literature search was performed on PubMed and Embase, targeting articles reporting use of antihistamine for purposes other than itch and urticaria control in dermatological practice. Several off-label usages of antihistamines were identified, including alopecia, acne, Darier disease, eosinophilic dermatoses, paraneoplastic dermatoses, psoriasis, lichen nitidus, radiation dermatitis, skin dysesthesia, and cutaneous malignancies. Additional benefits were observed when H-1 antihistamines were used either alone or in combination with other therapeutic modalities. Although various novel uses of H-1 antihistamines have been uncovered, the evidence level of most included studies is weak. Further randomized control trials are warranted to better evaluate the efficacy and dosage of H-1 antihistamine for dermatological disorders. ? 2021, The Author(s).Anti-inflammation; Dermatology; H-1 antihistamines; Off-label usages; Pleiotropic effects[SDGs]SDG3analgesic agent; antihistaminic agent; astemizole; azelastine; bepotastine; bilastine; bromocriptine; cetirizine; chlorpheniramine; clemastine; clobetasol; corticosteroid; cyproheptadine; desloratadine; diphencyprone; diphenhydramine; ebastine; fexofenadine; gabapentin; histamine H1 receptor antagonist; hydroxyzine; intercellular adhesion molecule 1; isotretinoin; ketotifen; levocetirizine; loratadine; montelukast; oxatomide; pizotifen; pregabalin; ranitidine; sertraline; steroid; terfenadine; acanthosis nigricans; acne; acromegaly; adjuvant therapy; adult; alopecia areata; analgesic activity; antiinflammatory activity; antiviral activity; atopic dermatitis; basophil; bullous skin disease; burning sensation; chemotaxis; clinical practice; corticosteroid therapy; Darier disease; drug mechanism; dysesthesia; Embase; eosinophil; eosinophilic fasciitis; eosinophilic pustular folliculitis; erythromelalgia; folliculitis; growth hormone release; human; hypereosinophilic syndrome; in vitro study; Kaposi sarcoma; keratinocyte; lichen (disease); lichen planopilaris; lichenoid eruption; male; male type alopecia; mast cell; mediator release; Medline; melanoma; middle aged; neutrophil chemotaxis; protein expression; protein secretion; pruritus; psoriasis; radiation dermatitis; randomized controlled trial (topic); Review; scalp dysesthesia; sebum secretion; skin disease; systematic review; treatment response; unspecified side effect; urticaria; Wells syndromereview10.1007/s13555-021-00524-w2-s2.0-85104375038